Please login to the form below
KRAS
This page shows the latest KRAS news and features for those working in and with pharma, biotech and healthcare.
Routine gene test could guide use of cancer chemotherapy, new study shows
Separate data from a clinical trial showed that patients with another mutation in the KRAS gene called KRASG13 – 8% of those in the study – saw their median survival triple with the ... treatment. For those without KRAS mutations, survival was found
Latest news
-
Amgen announces positive results for Lumakras colorectal cancer combination treatment
KRAS mutations are among the most common genetic alterations in colorectal cancers, with the KRAS G12C mutation present in approximately 3-5% of colorectal cancers. ... In total, 40 patients with heavily pre-treated KRAS G12C-mutated chemo-refractory
-
Amgen’s Lumakras shows promising results for patients with non-small cell lung cancer
Results from the phase 3 trial demonstrated superiority over standard of care Docetaxel chemotherapy in KRAS G12C-mutated non-small cell lung cancer. ... KRAS G12C is the most common KRAS mutation in NSCLC, with around 13% of patients with NSCLC
-
NICE recommends Amgen’s Lumykras for non-small-cell lung cancer
lung cancers and approximately 13% of these are believed to carry the KRAS G12C mutation. ... The CMA for Lumykras is based on clinical evidence from the phase 2 CodeBreaK 100 trial which evaluated the drug in 126 patients with KRAS G12C- mutated
-
Amgen’s Lumakras shows promising results for patients with advanced pancreatic cancer
The results from the phase 1/2 trial showed encouraging and clinically meaningful anticancer activity in patients with the KRAS G12C-mutation. ... The CodeBreaK 100 phase 1/2 trial assessed the drug’s safety and effectiveness profile for patients with
-
Amgen’s Lumykras receives conditional marketing authorisation from EC
The drug is the first targeted therapy for patients diagnosed with advanced NSCLC with the KRAS G12C mutation. ... To date, the trial is the largest conducted for patients diagnosed with the KRAS G12C mutation.
More from news
Approximately 7 fully matching, plus 31 partially matching documents found.
Latest Intelligence
-
Encouraging signs in biomarker R&D
The questions being asked are, what does an individual’s mutational profile look like, and do we have a drug to treat it; ie, do they have EGFR mutations, KRAS or
-
Interview: AstraZeneca's Susan Galbraith
This includes people with NSCLC who have a mutated KRAS gene - an area where no specific treatment option exists. ... With selumetinib you've now got that plus another 20-25 per cent of NSCLC cases - people with the KRAS mutation.”.
-
Pharma deals during September 2012
advanced KRAS; a wild-type metastatic colorectal cancer (mCRC). ... 665. Symphogen / Merck KGaA. Product licence. Sym004 for advanced KRAS; a wild-type metastatic colorectal cancer (mCRC) (phase I /II).
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
BIND Therapeutics appoints Andrew Hirsch as permanent CEO
Its lead compound, BIND-014, is currently in phase II clinical trials for KRAS-mutant and squamous histology non-small cell lung cancer.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Putting Skin in the Game at AAD 2023
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- NHS England announces rare genetic disorder fast-tracking service
- NICE sees ‘promise’ in four UTI tests that could help in fight against AMR
- Connectome competitiveness
- Humancomms for humancare?
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Trust me, I’m from pharma
- Sobi’s Kineret granted FDA Emergency Use Authorisation for COVID-19 related pneumonia
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- Genmab hires first chief operating officer
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
Latest intelligence
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
